Cefepime, not Piperacillin/Tazobactam use, for empirical treatment of bloodstream infections caused by Enterobacter spp.: Results from a population pharmacokinetic/pharmacodynamic analysis

•Enterobacter spp. is derived from largest blood antimicrobial surveillance network.•Cefepime, not piperacillin/tazobactam, is suitable in empirically treating Enterobacter spp..•Therapeutic drug monitoring is needed in patients with renal impairment.•Intensified imipenem/cefepime dosing is supported by pharmacokinetic modeling.